Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letermovir for prevention of CMV infection after allogeneic HSCT in CMV-seropositive adults (China, Phase III)
CTR20230289Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of letermovir in cytomegalovirus disease (CMV), sponsored by Merck & Co. Primary endpoint: Clinically significant CMV infection through week 24 post-transplant. Started Feb 2023; status: completed.
02
Drugs
letermovir
03
Conditions
cytomegalovirus disease (CMV)
Beyond the preview
Go deeper on CTR20230289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230289.